

A2
cancd.

12. The process of claim 2, wherein said peptide to be purified is selected from glucagon, hGH, insulin, FactorVII, FactorVIIa, FactorVIIai, FFR-FactorVIIa, glucagon-like peptide-1, glucagon-like peptide-2 and analogs, as well as derivatives thereof.

13. The process of claim 2, wherein the ratio of organic modifier to water on a weight percent basis is from 1:99 to 99:1.


14. The process of claim 2, wherein the organic modifier is selected from C₁₋₆-alkanol, C₁₋₆-alkenol, C₁₋₆-alkynol, urea, guanidine, C₁₋₆-alkanoic acid, C₂₋₆-glycol, or C₃₋₇-polyalcohol.--

REMARKS

This application is a divisional of copending application no. 09/522,694. Claims 1, 3, 5 and 7-10 have been canceled and claims 11-14 have been added. Therefore, claims 2, 4, 6 and 11-13 are pending in the present application. Support for new claims 11-14 can be found, for example, in the specification at pages 6, lines 2-7 and page 4, lines 1-2 and 5-7. Claims 2, 4, 6 and 11-14 are directed to the invention of **Group II** that was not elected in 09/522,694. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: September 27, 2000


Carol E. Rozek, Reg. No. 36,993
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123